|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DMWD |
Gene summary for DMWD |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DMWD | Gene ID | 1762 |
| Gene name | DM1 locus, WD repeat containing | |
| Gene Alias | D19S593E | |
| Cytomap | 19q13.32 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q09019 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1762 | DMWD | C21 | Human | Oral cavity | OSCC | 1.96e-06 | 3.10e-01 | 0.2678 |
| 1762 | DMWD | C30 | Human | Oral cavity | OSCC | 9.16e-19 | 8.44e-01 | 0.3055 |
| 1762 | DMWD | C38 | Human | Oral cavity | OSCC | 1.70e-02 | 6.34e-01 | 0.172 |
| 1762 | DMWD | C43 | Human | Oral cavity | OSCC | 7.84e-08 | 1.50e-01 | 0.1704 |
| 1762 | DMWD | C46 | Human | Oral cavity | OSCC | 1.52e-10 | 1.42e-01 | 0.1673 |
| 1762 | DMWD | C51 | Human | Oral cavity | OSCC | 4.06e-02 | 3.37e-01 | 0.2674 |
| 1762 | DMWD | C08 | Human | Oral cavity | OSCC | 7.63e-10 | 2.33e-01 | 0.1919 |
| 1762 | DMWD | C09 | Human | Oral cavity | OSCC | 6.29e-03 | 1.70e-01 | 0.1431 |
| 1762 | DMWD | LN22 | Human | Oral cavity | OSCC | 7.15e-03 | 6.37e-01 | 0.1733 |
| 1762 | DMWD | NEOLP-2 | Human | Oral cavity | NEOLP | 3.71e-02 | 1.14e-01 | -0.0196 |
| 1762 | DMWD | SYSMH1 | Human | Oral cavity | OSCC | 1.99e-06 | 2.00e-01 | 0.1127 |
| 1762 | DMWD | SYSMH2 | Human | Oral cavity | OSCC | 2.93e-07 | 2.26e-01 | 0.2326 |
| 1762 | DMWD | SYSMH3 | Human | Oral cavity | OSCC | 2.66e-15 | 3.45e-01 | 0.2442 |
| 1762 | DMWD | SYSMH5 | Human | Oral cavity | OSCC | 9.83e-13 | 2.77e-01 | 0.0647 |
| 1762 | DMWD | SYSMH6 | Human | Oral cavity | OSCC | 4.76e-04 | 1.19e-01 | 0.1275 |
| 1762 | DMWD | male-WTA | Human | Thyroid | PTC | 3.75e-14 | 1.43e-01 | 0.1037 |
| 1762 | DMWD | PTC01 | Human | Thyroid | PTC | 5.36e-04 | 1.27e-01 | 0.1899 |
| 1762 | DMWD | PTC04 | Human | Thyroid | PTC | 9.72e-13 | 1.68e-01 | 0.1927 |
| 1762 | DMWD | PTC05 | Human | Thyroid | PTC | 4.54e-05 | 2.52e-01 | 0.2065 |
| 1762 | DMWD | PTC06 | Human | Thyroid | PTC | 8.25e-19 | 4.39e-01 | 0.2057 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DMWD | SNV | Missense_Mutation | novel | c.1929N>C | p.Gln643His | p.Q643H | Q09019 | protein_coding | tolerated_low_confidence(0.23) | probably_damaging(0.948) | TCGA-AQ-A7U7-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Targeted Molecular therapy | rituximab | CR |
| DMWD | SNV | Missense_Mutation | novel | c.466N>A | p.Asp156Asn | p.D156N | Q09019 | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-C8-A133-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| DMWD | SNV | Missense_Mutation | novel | c.1781N>G | p.Glu594Gly | p.E594G | Q09019 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| DMWD | SNV | Missense_Mutation | rs778597417 | c.746N>T | p.Ser249Leu | p.S249L | Q09019 | protein_coding | tolerated(0.21) | benign(0.07) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| DMWD | SNV | Missense_Mutation | novel | c.966N>A | p.Met322Ile | p.M322I | Q09019 | protein_coding | deleterious(0.01) | possibly_damaging(0.838) | TCGA-C5-A7CK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| DMWD | SNV | Missense_Mutation | c.687N>G | p.Phe229Leu | p.F229L | Q09019 | protein_coding | deleterious(0.04) | benign(0.039) | TCGA-EK-A2RJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| DMWD | SNV | Missense_Mutation | novel | c.408C>G | p.Phe136Leu | p.F136L | Q09019 | protein_coding | tolerated(0.07) | possibly_damaging(0.899) | TCGA-MA-AA41-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| DMWD | SNV | Missense_Mutation | c.1002G>C | p.Trp334Cys | p.W334C | Q09019 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| DMWD | SNV | Missense_Mutation | rs755365606 | c.1075N>T | p.Arg359Cys | p.R359C | Q09019 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-VS-A9U6-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| DMWD | SNV | Missense_Mutation | novel | c.500N>A | p.Cys167Tyr | p.C167Y | Q09019 | protein_coding | deleterious(0) | benign(0.078) | TCGA-A6-2672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |